» Articles » PMID: 20075158

Amino Acid Residues Arg(659), Arg(660), and Tyr(661) in the Spacer Domain of ADAMTS13 Are Critical for Cleavage of Von Willebrand Factor

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2010 Jan 16
PMID 20075158
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have shown that ADAMTS13 spacer domain is required for cleavage of von Willebrand factor (VWF). However, the exact amino acid residues within this domain critical for substrate recognition are not known. Epitope mapping of anti-ADAMTS13 immunoglobulin G from patients with thrombotic thrombocytopenic purpura and sequence alignment of the ADAMTS13 spacer domains of human, mouse, and zebrafish with these of human and murine ADAMTS1, a closely related member of ADAMTS family, have provided hints to investigate the role of the amino acid residues between Arg(659) and Glu(664) of the ADAMTS13 spacer domain in substrate recognition. A deletion of all these 6 amino acid residues (ie, Arg(659)-Glu(664)) from the ADAMTS13 spacer domain resulted in dramatically reduced proteolytic activity toward VWF73 peptides, guanidine-HCl denatured VWF, and native VWF under fluid shear stress, as well as ultralarge VWF on endothelial cells. Site-directed mutagenesis, kinetic analyses, and peptide inhibition assays have further identified a role for amino acid residues Arg(659), Arg(660), and Tyr(661) in proteolytic cleavage of various substrates under static and fluid shear stress conditions. These findings may provide novel insight into the structural-function relationship of ADAMTS13 and help us to understand pathogenesis of thrombotic thrombocytopenic purpura and other arterial thromboses associated with compromised VWF proteolysis.

Citing Articles

Autoantibodies to ADAMTS13 in human immunodeficiency virus-associated thrombotic thrombocytopenic purpura.

Meiring M, Khemisi M, Louw S, Krishnan P Vox Sang. 2024; 119(12):1285-1294.

PMID: 39293938 PMC: 11634445. DOI: 10.1111/vox.13738.


Animal models for thrombotic thrombocytopenic purpura: a narrative review.

Zheng L, Zheng X Ann Blood. 2024; 8.

PMID: 39148951 PMC: 11326488. DOI: 10.21037/aob-22-18.


Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.

Zheng X J Thromb Haemost. 2024; 22(5):1358-1365.

PMID: 38360215 PMC: 11055658. DOI: 10.1016/j.jtha.2024.02.003.


Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.

Halkidis K, Meng C, Liu S, Mayne L, Siegel D, Zheng X Blood. 2023; 141(24):2993-3005.

PMID: 37023370 PMC: 10315623. DOI: 10.1182/blood.2022019252.


Mechanisms of ADAMTS13 regulation.

DeYoung V, Singh K, Kretz C J Thromb Haemost. 2022; 20(12):2722-2732.

PMID: 36074019 PMC: 9826392. DOI: 10.1111/jth.15873.


References
1.
Zheng X, Nishio K, Majerus E, Sadler J . Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem. 2003; 278(32):30136-41. PMC: 11033693. DOI: 10.1074/jbc.M305331200. View

2.
Siedlecki C, Lestini B, Eppell S, Wilson D, Marchant R . Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996; 88(8):2939-50. View

3.
Raife T, Cao W, Atkinson B, Bedell B, Montgomery R, Lentz S . Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood. 2009; 114(8):1666-74. PMC: 2731642. DOI: 10.1182/blood-2009-01-195461. View

4.
Tao Z, Wang Y, Choi H, Bernardo A, Nishio K, Sadler J . Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. Blood. 2005; 106(1):141-3. PMC: 1895119. DOI: 10.1182/blood-2004-11-4188. View

5.
Ai J, Smith P, Wang S, Zhang P, Zheng X . The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem. 2005; 280(33):29428-34. PMC: 2577221. DOI: 10.1074/jbc.M505513200. View